Recurrent pregnancy loss (RPL) is defined in the United States as two or more consecutive failed clinical pregnancies documented by ultrasound or histopathology. In the United Kingdom, it is defined as having three or more consecutive early pregnancy losses.
Only about 2 percent of pregnant women have two consecutive pregnancy losses. Up to 50 percent of patients with RPL have no clearly defined etiology. RPL is one of the complex and challenging scenarios in reproductive medicine, and it is frustrating for the patients, their families, and treating physicians as well. When the etiology of RPL is unclear, it can create anxiety and apprehension among the patients.
RPL can be categorized into primary and secondary; primary RPL refers to pregnancy loss in women who never had a live birth. In contrast, secondary RPL is defined as pregnancy loss in women who had a previous live birth.
The etiology of recurrent pregnancy loss (RPL) is broadly classified into the following:
Genetic: Aneuploidy is one of the most common causes of RPL. Balanced, reciprocal, and Robertsonian translocations in the fetus can predispose to spontaneous miscarriages.
Anatomic: Congenital Mullerian tract anomalies can cause RPL. Some of the uterine abnormalities which can predispose to RPL are septate, unicornuate, bicornuate, didelphic, and arcuate uteri. Septate uterus is considered to be the most common congenital uterine anomaly. A meta-analysis of several studies concluded that congenital uterine defects were present in about 12.6 percent of the patients with recurrent pregnancy loss. Acquired uterine anomalies like fibroids, polyps, and Asherman syndrome can also increase the women's risk for RPL.
Endocrine: Maternal endocrine disorders like diabetes and thyroid dysfunction can cause RPL and must be evaluated and appropriately treated in patients with RPL. Hyperprolactinemia may be associated with RPL but is not proven.
Antiphospholipid antibody syndrome (APLS): accounts for about 8 to 42 percent of patients with RPL. APLS causes an increased risk of thrombosis and placental insufficiency, causing RPL.
Environmental factors: Cigarette smoking is suggested to affect the trophoblastic function and is linked to an increased risk of RPL. Obesity is independently associated with an increased risk of recurrent pregnancy loss in women who conceive naturally. Other lifestyle habits such as alcohol consumption (3 to 5 drinks per week), cocaine use, and increased caffeine consumption (more than 3 cups of coffee per day), are also associated with increased risk of spontaneous miscarriages.
Immunological: Routine testing of women with RPL for inherited thrombophilias is not currently recommended. Screening for inherited thrombophilias may be indicated when a patient has a personal history of venous thromboembolism in the setting of a nonrecurrent risk factor (such as surgery) or a relative with a known or suspected high-risk thrombophilia. Prospective cohort studies have failed to confirm the association between hereditary thrombophilia and fetal loss.
RPL is a multifactorial condition that may be due to genetic, anatomic, endocrine, antiphospholipid antibody syndrome, immunologic, and environmental factors.
FOXD1 mutations play a central role in RPL. FOXD1 was defined as a major molecule involved in embryo implantation in mice and humans by regulating endometrial and placental genes. FOXD1 mutations in human species have been functionally linked to RPL's origin.
A thorough and detailed history should be taken and must include all the details of previous pregnancy losses. The gestational age of prior pregnancy loss is critical to know, as RPL typically occurs at a similar gestational age in the successive pregnancies. The method of treatment of previous pregnancy loss is also important to know, as dilation and curettage can increase the risk of Asherman syndrome, cervical incompetence, which can predispose to RPL.
It is also essential to document full medical (thyroid problems, diabetes), surgical, and menstrual history. Family and personal history of venous and arterial thrombosis, history of smoking, alcohol, drugs, and exposure to environmental toxins must be documented. Physical examination should include a detailed general exam and pelvic exam.
Evaluation of couples with RPL should be thorough and should include the following:
Assessment of Medical Problems
Studies should be performed to rule out diabetes, thyroid problems , and hyperprolactinemia.
Karyotype assessment of the couples has to be offered to recognize underlying balanced, reciprocal, or Robertsonian translocations or mosaicism that might be transmitted to the fetus, causing RPL. Though these tests are of low yield and expensive, one should consider evaluating the karyotypes of the couples with RPL.
Assessment of the Uterine Anomalies
There are several modalities which can be used to identify congenitally and acquired uterine anomalies, some of the valuable tools are the following:
Immunologic Work Up
Investigations for antiphospholipid antibody syndrome must be undertaken. Measurement of Anticardiolipin antibody, lupus anticoagulant, and anti-beta 2 glycoprotein should be done for patients with RPL. Studies have reported that anticardiolipin antibody and lupus anticoagulant has been associated with pregnancy loss, and testing for APAS for patients with RPL is recommended.
Routine assessment of serum progesterone levels is not recommended, as it is not predictive of future pregnancy outcomes.
A large number of studies show that this test is not reflective of fertility status in a woman.
Testing for Infections
In a healthy woman without symptoms, routine vaginal and cervical cultures for chlamydia, gonorrhea, bacterial vaginosis, and testing for TORCH serology are not useful in the evaluation of RPL.
Evaluation of products of Conception (POC)
Using a 24-chromosome microarray analysis adds significantly to the ASRM (American Society of Reproductive Medicine) recommended RPL assessment. Genetic evaluation of miscarriage tissue obtained at the time of the second and subsequent pregnancy losses should be offered to all couples with two or more consecutive pregnancy losses. The combination of a genetic evaluation on miscarriage tissue with an evidence-based assessment for RPL will identify a probable or definitive cause in over 90 percent of miscarriages.
The treatment of RPL should be directed towards the underlying treatable cause. Patients and their families should be informed about the risks, alternatives, and success rates of each available treatment option. Treatment success can be increased by providing emotional support for these anxious couples. There should be collaborative teamwork and clear communication between reproductive endocrinologists and obstetricians, whenever possible.
Women with thyroid conditions, diabetes, obesity, and other medical problems should be treated as medically appropriate. Consultation with an endocrinologist is also a suitable option for the management of uncontrolled thyroid conditions and diabetes. Patients with elevated thyroid peroxidase antibodies are at high risk for RPL and should be managed appropriately.
In couples with chromosomal abnormalities, the first step is a referral to genetic counseling. Couples should be educated on the potential likelihood of having fetal chromosomal abnormalities in future pregnancies. They may choose to proceed with
prenatal genetic testing, such as preimplantation genetic diagnosis, chorionic villus sampling, or amniocentesis to identify genetic anomalies in the fetus and decide about further treatment options. Although embryos with unbalanced chromosomal arrangements can theoretically be screened out, PGT (preimplantation genetic testing) is not routinely advised since the likelihood of a pregnancy with an unbalanced karyotype surviving into the second trimester is low.
Uterine Anomalies Congenital and acquired uterine abnormalities causing RPL could be managed surgically. Some of the surgical procedures are hysteroscopic septum resection, lysis of adhesions, myomectomy, and repair of a bicornuate uterus. Referral to a reproductive endocrinologist is appropriate for these surgical interventions whenever possible.
Patients with antiphospholipid antibody syndrome and RPL are generally treated with aspirin and heparin, and it appears to improve pregnancy outcomes. However, in women with thrombophilias, this treatment may improve maternal outcomes but does not prevent RPL. Treatment strategies like aspirin and low molecular weight heparin (LMWH) are standard medications in RPL, although only a few placebo-controlled trials have proven their benefit with respect to live birth rate. There is emerging evidence that new treatment options, including drugs like TNF (tumor necrosis factor-alpha) inhibitors and granulocyte colony-stimulating factor (G-CSF), might be beneficial in some cases of RPL. However, more extensive clinical trials must be completed to further prove or disprove the benefits of these drugs in the treatment of patients with RPL. Lipid emulsion infusions has been evaluated in only one RCT that tested whether a 250 mL infusion on the day of oocyte retrieval (with further infusions if there was a positive pregnancy test) could increase chemical pregnancy rates in patients with RPL with elevated peripheral blood NK cells (more than 12 percent) undergoing IVF. The study concluded that Intralipid supplementation did not increase the frequency of chemical pregnancy. However, findings related to ongoing pregnancy and live birth should be investigated further.
A recent meta-analysis using strict criteria for defining unexplained RM found no RCTs involving prednisolone. Two recent meta-analyses of intravenous immunoglobulin (IVIG) use in patients with RPL found no evidence of improved live birth rates.
The Progesterone in Recurrent Miscarriage (PROMISE) trial involved 836 women with idiopathic recurrent miscarriage randomized to receive either 400 mg of vaginal micronized progesterone twice daily or placebo from the time of positive pregnancy test to 12 weeks gestation. There was no difference between the two groups in miscarriage or live birth rates. In contrast, another RCT involving 700 women also tested whether the same dose of vaginally administered natural progesterone would benefit unexplained RPL, but unlike the PROMISE trial, that trial commenced treatment in the luteal phase immediately after documentation of ovulation using either ultrasound or luteinizing hormone (LH) kits and continued until 28 weeks gestation. This Egyptian trial found significantly lower miscarriage rates (12.4 versus 23.3 percent) and higher live birth rates (92 versus 77 percent) in the treated group.
Recurrent pregnancy loss (RPL) carries a tremendous negative emotional and psychological negative impact on couples. It is associated with depression, anxiety, and low self-esteem. Increasing maternal age, as well as the number of previous miscarriages, appear to be the most influential independent risk factors for having further pregnancy losses.
Women who experience recurrent pregnancy loss can struggle emotionally and mentally as this diagnosis carries an adverse impact on the women and their families. The couple can suffer due to the psychological impact of repeated pregnancy loss and the feeling that the problem might never end. RPL carries a great deal of frustration, and the couples are continuously aspiring to achieve a successful pregnancy and simultaneously afraid of miscarrying again. RPL carries a negative impact not only for women and their families but also for treating clinicians. It could leave couples with negative emotions like anger, sadness, frustration, and confusion. It could also affect relationships and results in a loss of intimacy.
Patient education is key to the successful management of couples with recurrent pregnancy loss. Healthcare providers play a crucial role in managing couples with RPL. Approaching couples with RPL in a sensitive manner and appreciating their needs, concerns, and their preferences, taking into account their cultural differences, religious obligations, and wishes is core to the optimal management of this severe diagnosis. The best possible outcomes for couples with RPL can not be achieved without the active role of every member in the interprofessional team, with regards to helping their patients and their families make informed decisions about their care.
Recurrent pregnancy loss represents a complex challenge in reproductive medicine and causes frustration for the patients, their families, and the healthcare team. Healthcare practitioners should thoroughly counsel patients with recurrent pregnancy loss so that they can make informed decisions about whether they want to go through extensive investigations and treatment. Interprofessional collaboration between endocrinologists, obstetricians, nurses, midwives, and geneticists plays a crucial role in helping couples with recurrent pregnancy loss throughout their journey.
The nurse should assist the clinician during the investigations and management of couples with recurrent pregnancy loss. The nurse should educate the woman and her family regarding the possible etiologies of their condition and explain the required investigations. The counseling of women with recurrent pregnancy loss requires sensitivity, and the negative emotional burden of their disease merits careful consideration at all times. The provides should provide women with written information leaflets on recurrent pregnancy loss, to help them better understand their disease and make informed decisions about their care. Ideally, women should be counseled preconceptionally about the possible underlying modifiable risk factors, such as alcohol, smoking, and caffeine consumption. Women should be advised about taking folic acid in preparation for pregnancy. RPL carries a tremendous negative impact on women and their families. Therefore, women could benefit from regular follow up visits with their clinician, interprofessional meetings, and psychotherapy, should it deemed necessary. The providers should inform the couple that there is no specific recommendation that could guarantee the outcome in future pregnancies. Couples with recurrent pregnancy loss need to understand that they have a high chance of having a live birth without any treatments, even after frequent pregnancy losses. The nurse should assist the clinician in screening couples with RPL for depression and anxiety and should refer couples immediately to mental health specialists, should it deemed necessary. The nurse should inform the clinician about any concerns the couple might have throughout their treatment journey.
The members of the interprofessional team should ensure that couples with RPL have access to the available community resources. The nurse should provide appropriate referrals to couples with RPL to the patient support groups that could help them cope with the negative emotional burden of their condition. The best possible outcome for couples with recurrent pregnancy loss is not achievable without the harmonious collaboration between the members of the interprofessional team with the core principle of patient-centered care.
|||Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and sterility. 2013 Jan; [PubMed PMID: 23095139]|
|||Salat-Baroux J, [Recurrent spontaneous abortions]. Reproduction, nutrition, developpement. 1988; [PubMed PMID: 3073445]|
|||Stephenson MD, Frequency of factors associated with habitual abortion in 197 couples. Fertility and sterility. 1996 Jul; [PubMed PMID: 8752606]|
|||Ansari AH,Kirkpatrick B, Recurrent pregnancy loss. An update. The Journal of reproductive medicine. 1998 Sep; [PubMed PMID: 9777621]|
|||Grimbizis GF,Camus M,Tarlatzis BC,Bontis JN,Devroey P, Clinical implications of uterine malformations and hysteroscopic treatment results. Human reproduction update. 2001 Mar-Apr; [PubMed PMID: 11284660]|
|||Yetman DL,Kutteh WH, Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertility and sterility. 1996 Oct; [PubMed PMID: 8816614]|
|||Practice Bulletin No. 132: Antiphospholipid syndrome. Obstetrics and gynecology. 2012 Dec; [PubMed PMID: 23168789]|
|||Barišić A,Pereza N,Hodžić A,Krpina MG,Ostojić S,Peterlin B, Genetic variation in the maternal vitamin D receptor FokI gene as a risk factor for recurrent pregnancy loss. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2019 Sep 16 [PubMed PMID: 31446814]|
|||Negro R,Schwartz A,Gismondi R,Tinelli A,Mangieri T,Stagnaro-Green A, Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. The Journal of clinical endocrinology and metabolism. 2010 Sep; [PubMed PMID: 20534758]|
|||Clark DA,Daya S,Coulam CB,Gunby J, Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group. American journal of reproductive immunology (New York, N.Y. : 1989). 1996 May; [PubMed PMID: 8738721]|
|||ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2002 Aug; [PubMed PMID: 12360906]|
|||Pellerito JS,McCarthy SM,Doyle MB,Glickman MG,DeCherney AH, Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography. Radiology. 1992 Jun; [PubMed PMID: 1584936]|
|||Cervera R,Balasch J, Autoimmunity and recurrent pregnancy losses. Clinical reviews in allergy [PubMed PMID: 19842070]|
|||Idowu D,Merrion K,Wemmer N,Mash JG,Pettersen B,Kijacic D,Lathi RB, Pregnancy outcomes following 24-chromosome preimplantation genetic diagnosis in couples with balanced reciprocal or Robertsonian translocations. Fertility and sterility. 2015 Apr [PubMed PMID: 25712573]|
|||Negro R,Formoso G,Mangieri T,Pezzarossa A,Dazzi D,Hassan H, Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. The Journal of clinical endocrinology and metabolism. 2006 Jul; [PubMed PMID: 16621910]|
|||Otani T,Roche M,Mizuike M,Colls P,Escudero T,Munné S, Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies. Reproductive biomedicine online. 2006 Dec; [PubMed PMID: 17169213]|
|||Franssen MT,Korevaar JC,van der Veen F,Leschot NJ,Bossuyt PM,Goddijn M, Reproductive outcome after chromosome analysis in couples with two or more miscarriages: index [corrected]-control study. BMJ (Clinical research ed.). 2006 Apr 1 [PubMed PMID: 16495333]|
|||Heinonen PK,Saarikoski S,Pystynen P, Reproductive performance of women with uterine anomalies. An evaluation of 182 cases. Acta obstetricia et gynecologica Scandinavica. 1982; [PubMed PMID: 7113692]|
|||Toth B,Vomstein K,Togawa R,Böttcher B,Hudalla H,Strowitzki T,Daniel V,Kuon RJ, The impact of previous live births on peripheral and uterine natural killer cells in patients with recurrent miscarriage. Reproductive biology and endocrinology : RB&E. 2019 Aug 31 [PubMed PMID: 31472670]|
|||Dakhly DM,Bayoumi YA,Sharkawy M,Gad Allah SH,Hassan MA,Gouda HM,Hashem AT,Hatem DL,Ahmed MF,El-Khayat W, Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2016 Dec [PubMed PMID: 27614789]|
|||Rasmark Roepke E,Hellgren M,Hjertberg R,Blomqvist L,Matthiesen L,Henic E,Lalitkumar S,Strandell A, Treatment efficacy for idiopathic recurrent pregnancy loss - a systematic review and meta-analyses. Acta obstetricia et gynecologica Scandinavica. 2018 Mar 30 [PubMed PMID: 29603135]|
|||Coomarasamy A,Williams H,Truchanowicz E,Seed PT,Small R,Quenby S,Gupta P,Dawood F,Koot YE,Bender Atik R,Bloemenkamp KW,Brady R,Briley AL,Cavallaro R,Cheong YC,Chu JJ,Eapen A,Ewies A,Hoek A,Kaaijk EM,Koks CA,Li TC,MacLean M,Mol BW,Moore J,Ross JA,Sharpe L,Stewart J,Vaithilingam N,Farquharson RG,Kilby MD,Khalaf Y,Goddijn M,Regan L,Rai R, A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. The New England journal of medicine. 2015 Nov 26 [PubMed PMID: 26605928]|
|||Ismail AM,Abbas AM,Ali MK,Amin AF, Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2018 Feb [PubMed PMID: 28114846]|